Evidence map›Paper›PMID 33262329›Full record

ArticleCell death & disease2020

Inhibition of EZH2 ameliorates bacteria-induced liver injury by repressing RUNX1 in dendritic cells.

Yanan Wang, Qiwei Wang, Bei Wang, Yuting Gu, Hongshuang Yu, Wanlin Yang, Xiaohui Ren, Fengtao Qian, Xiaonan Zhao, Yichuan Xiao and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. CBS-HJournal of advanced research · 2023
    Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Yanan WangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qiwei WangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bei WangCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Yuting GuDepartment of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hongshuang YuCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Wanlin YangInstitutes for Translational Medicine, Soochow University, Suzhou, China.
Xiaohui RenCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Fengtao QianCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Xiaonan ZhaoInstitutes for Translational Medicine, Soochow University, Suzhou, China.
Yichuan XiaoCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-7804-6971
Yanyun ZhangShanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. yyzhang@sibs.ac.cn.
Min JinCAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China. mjin@sibs.ac.cn.
Meiling ZhuDepartment of Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. zhumeiling@xinhuamed.com.cn.
Shanghai Jiao Tong University · CNShanghai Institute of Nutrition and Health · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fulminant hepatic failure (FHF) is a clinical syndrome characterized by a sudden and severe impairment in liver function. However, the precise mechanism of immune dysregulation that is significant to FHF pathogenesis remains unclear. Enhancer of zeste homolog 2 (EZH2) has been implicated in inflammation as a regulator of immune cell function. In this study, we investigated the role of EZH2 in an animal model of human FHF induced by Propionibacterium acnes (P. acnes) and lipopolysaccharide (LPS). We demonstrated that EZH2 depletion in dendritic cells (DCs) and pharmacological inhibition of EZH2 using GSK126 both significantly ameliorated liver injury and improved the survival rates of mice with P. acnes plus LPS-induced FHF, which could be attributed to the decreased infiltration and activation of CD4

Indexed as

AnimalsChemical and Drug Induced Liver Injury, ChronicCore Binding Factor Alpha 2 SubunitDendritic CellsEnhancer of Zeste Homolog 2 ProteinFemaleHumansLiver Failure, AcuteMicePropionibacterium acnesCore Binding Factor Alpha 2 SubunitEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseRunx1 protein, mouse

Identifiers

PMID33262329
PMCPMC7708645
OpenAlexW3108338894

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.